

Questions and Answers

1. Does HSV recognise the regulations and testing standards of both RCPA and NATA?

HSV have engaged with the Pathology Equipment Executive Reference Group (ERG) and the Pathology Consumables Product Reference Group (PRG), both comprising experts from across the health services sector. These groups have contributed to and endorsed the strategy and specifications for their respective Invitations to Supply (ITS), which will include any applicable regulations or standards.

Please note this ITS is a supplier prequalification process, therefore we are not awarding specific products, hence not reviewing against these regulations or standards. When individual health services develop their health service specific requirements at time of acquisition, they will determine exactly what requirements suppliers must meet.

2. Can I please ask the Timeline, tender release 25/6/25 and then submission date?

The tender is expected to be released the week commencing Monday 30 June 2025. A notification will be sent out to suppliers that had registered for the supplier briefing. Information will also be available on the [HSV website](#) and the slide deck from the presentation.

3. Will a copy of the slide deck (presentation) be available online?

A copy is now available for download on the [HSV website](#)

4. Are there major changes to the T&Cs or do they mimic the current T&Cs?

There will be some changes. We expect it to be an improvement for suppliers as a lot of the changes are based on agreed positions with suppliers from previous activities. A lot of the major terms will remain consistent - however as always please review the MSA carefully and if any concerns we will work with suppliers on ensuring a fair and equitable outcome for all.

5. Regarding list pricing - this will vary for suppliers over the term of the agreement. is there a mechanism to update this as required?

Yes, there will. We will be seeking updated pricing every year or as changes occur from suppliers.

6. Could you consider an open industry meeting with your Legal counsel to discuss MSA terms that may still be of concern on the current version?

HSV will not be in a position at moment to undertake another industry briefing specific to the MSA. We are happy to work with all suppliers on this process to ensure ongoing improvement and outcomes are fair and equitable for all. Therefore, please review the MSA carefully and if any concerns we will work with suppliers throughout this process.

7. The requirement at present is that no departures will be accepted. From what you are saying above, am I correct that this means that you will not reject the submission immediately, but still consider

HSV will only review matters specific to the MSA where there are significant issues or exceptional circumstances; however, such cases are expected to be extremely rare. If any changes are necessary

due to extenuating circumstances, they will be considered or addressed in future revisions. HSV will not be considering amendments to the MSA we determine to be inconsequential.

8. Regarding TGA requirements, for molecular pathology there may be equivalent/superior systems available that are classed as "research use only". would the panel consider such a system?

The procurement of goods and services related to scientific and medical research is exempted from HSV Purchasing Policies therefore, out of scope from this Panel.

9. Regarding TGA requirements, is "pending ARTG" acceptable?

Please note this ITS is a supplier prequalification process, therefore we are not awarding specific products. Suppliers are encouraged to submit product information and pricing as instructed at today's briefing, which HSV will use for scope and funding purposes. At the time of purchasing by health services, equipment being tendered will require an ARTG# for health services to consider.